I surmise that a common question posed to an editor of a new journal is \"What is your impact factor?\" Based on my experience, in the majority of instances as the conversation evolves, it becomes evident that the questioner misunderstands what impact factor means. IF is a useful number. However, its limitations must be clearly recognized. Given the pervasive (if not obsessive) interest in IF, *Retrovirology*, as a new journal entering its fourth year of publication, has necessarily mined the citation databases and calculated IF numbers for 2005 (2.98) and 2006 (4.32) \[[@B1]\]. After having captured those numbers, it is perhaps instructive to consider some factual denotations and frequently misinterpreted connotations of IF. Indeed, as science and medicine march to a more personalized approach, one might further ask if it is time to embrace highly accessible technology in order to complement/supplant generic IF with individually precise citation metrics?

Impact Factor \-\-- what does it (not) say?
===========================================

In the 1960s, the Institute for Scientific Information (ISI), a component of Thomson Scientific, a division of The Thomson Corporation (a publicly traded company engaged in financial services, healthcare sectors, law, science and technology research, and tax and accounting services) devised the \"impact factor\" (IF), a number developed for the purpose of comparing different journals \[[@B2]\].

IF gauges the standing of a journal for a specified year. Hence, IF can be viewed as the mean number of citations that occurred in a specific year to articles published in a journal during the two previous years. In common vernacular, IF reflects the number of times an \"average article\" in a journal has been cited per year in the two immediately preceding years. A poorly-understood nuance to this definition is that IF disproportionately favors citations made during the first two years subsequent to a paper\'s publication, and does not accurately capture the paper\'s \"value\" over a longer time. Hypothetically, let\'s consider two papers that receive the same total number of citations (e.g. 100 times) over a 10 year period. Paper A is cited 80 times in its first two immediate calendar years after publication, and then 20 times over the subsequent eight years. Paper B is cited 20 times over the first two years and 80 times over the next eight years. Paper A fits the profile of an average article published by the journal *\"FlashyStuff\"*; while paper B is a usual paper in the journal \"*ReliablySolid*\". Within the context of this example, *FlashyStuff*would sport an IF of 40 while *ReliablySolid*would have an IF of 10. Intriguingly, the rather impressive 4 fold difference in impact factor belies common sense \-\-- that over ten years, a *FlashyStuff*article is cited no more frequently than a *ReliablySolid*paper (both exactly 100 times).

The above discussion briefly spotlights what IF in part does and does not convey. With that disclaimer, how is *Retrovirology*doing IF-wise as the journal enters its fourth year? Employing the algorithm that IF derives from the number of citations to a journal (by other ISI tracked journals) divided by the \"citable items\" published in the journal, in 2005 *Retrovirology*had a calculated IF of 2.98 based on ISI data. For 2006, *Retrovirology\'s*IF is calculated using the following parameters : N (numerator) = the number of times *Retrovirology*articles published in 2004 and 2005 were cited by other journals during the single 2006 year, and D (denominator) = the total number of citable *Retrovirology*articles published in years 2004 and 2005. *Retrovirology\'s*2006 IF is then N divided by D = 4.32.

How does 4.32 stack up against numbers from other journals? Figure [1](#F1){ref-type="fig"} compares *Retrovirology\'s*4.32 IF with recent IF numbers of other virology journals that frequently publish basic research on retroviruses. When measured against *Journal of Virology*, *Journal of General Virology*, *Virology*, *Current HIV Research*, *AIDS Research and Human Retroviruses*, and *Intervirology*, *Retrovirology*, the only Open Access publication amongst the seven, indeed rates very competitively (Fig. [1](#F1){ref-type="fig"}).

![A comparison of *Retrovirology\'s*calculated 2006 impact factor with selected journals that publish retrovirus research papers. Values for other journals are from ISI journal citation report for 2005.](1742-4690-4-42-1){#F1}

Now for something completely different?
=======================================

In the late 1970\'s when I began graduate school, large bulky word processing machines were just being invented, and small personal computers did not exist. This was a period when if one wished to learn what was being published, one had to reach for the weekly/monthly periodicals (that often meandered through the postal service sometimes, if it is a foreign journal, arriving months after publication) which were displayed on reading shelves in libraries. PubMed, other electronic databases, email, keyword e-alert, and instant table of contents notification were science fiction. In that era, it was laborious and time consuming to assess individually a journal\'s or a colleague\'s citation records. Hence, back then, judging a \"book by its cover\" or rating a paper based on the journal\'s IF would seem excusable simply because there was little other practical recourse.

In 2007, one can do much better. In the fifty years since the advent of IF, a couple of salient shortcomings to this index have been noted. First, an inherent quirk to IF definition allows the numerator to contain citations to \"non-citable\" items that are not counted in the denominator \[[@B3]\]. In general, \"non-citable\" items are the short newsy/opinion/commentary \"front matter\" pieces written by professional writers which appear frequently in many \"high impact\" journals. Citations to \"front matter\" pieces are tallied in the numerator for a journal\'s IF without a commensurate \"penalty\" added to the denominator. Hence, venues that publish numerous \"non-citable\" front matters have \"inflated\" IFs relative to counterparts that publish only \"citable\" articles (e.g. original research papers). Second, a journal\'s IF is a poor surrogate indicator of individual articles published in that journal. There is a statistical pattern to citations that on average 15% of the articles in a journal accounts for 50% of all citations to that journal, and the top 50% of articles in a journal garner 90% of citations to that journal \[[@B4]\]. Thus, a top 50% article can be cited 10 times more frequently than a bottom 50% article in the same journal \[[@B4]\]. Given the likelihood of a 10 fold difference in actual citations, why should colleagues assume that one *Cell/Science/Nature*paper has remotely the same value as another? Hence, even if one accepts citation frequency as a reflection of quality, there is little reason to adopt a journal\'s overall IF as a reliable touchstone for the gamut of papers published in that journal. The umbrella-like use of IF as a general quality tag seems all the more unnecessary since there are so many rapid and accessible options for tracking article-specific citations (e.g. Google Scholar, Scopus, and Web of Science \[[@B5]\]).

A couple of days ago, I read a remarkable news headline. \"James Watson of DNA fame gets his own genome map\". I recollected that when the first human genome sequencing was being done generic anonymity of that initial DNA was important. However, time has changed, and today James Watson (and you too) can have an individual genome sequenced rapidly and inexpensively. Is now not also the time that scientists should move to personalized measurements of citations? Aren\'t individual citation frequencies more thoughtful reflections of one\'s scientific corpus than the answer to the oft-bantered generic query \"How many *Cell/Science/Nature*papers has he/she published?\"

Today, one\'s individual citation frequency is easily accessible to all who have a few minutes to spend and internet access to databases. Google Scholar, Scopus, or Web of Science can each fully provide such information. Of the three, I found Scopus \[[@B6]\] to be the most user-friendly in its data organization and searchability. Hence, yesterday when I had a spare hour, I used Scopus to tabulate individual citation frequency and H index of 45 members of *Retrovirology\'s*editorial board (Table [1](#T1){ref-type="table"}). {The H index is another way to quantify a scientist\'s quality and quantity of scholarly output \[[@B7],[@B8]\]. This index attempts to combine and balance the effect of \"quantity\" (number of publications) and \"quality\" (citation rate) in a specific way.} I should point out that I did this data collection quickly (each person\'s numbers took no more than 1 minute), and as with all databases and human entries there can be errors (apologies to colleagues if I made mistakes with your numbers). Hence, please take table [1](#T1){ref-type="table"} to be illustrative rather than factually literal. Nevertheless, this elementary exercise echoes the words of a past US president, \"You can run, but you cannot hide.\" Like it or not, use it or not, each author\'s personalized citation number and H index are there for all to compare.

###### 

Citation frequency and H index for selected *Retrovirology*Editorial Board members (data collated on June 11, 2007 from Scopus).

  --------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Title**   **Name**             **Role within**\      **Institution**                **City**        **Country**       **H index**   **Total times cited**\
                                   ***Retrovirology***                                                                                  **since 1995**
  ----------- -------------------- --------------------- ------------------------------ --------------- ----------------- ------------- ------------------------
  Dr.         Kuan-Teh Jeang       Editor-in-Chief       NIH                            Bethesda        USA               39            7724

  Dr.         Monsef Benkirane     Editor                CNRS                           Montpellier     France            15            1371

  Dr.         Ben Berkhout         Editor                Academic Med. Ctr              Amsterdam       the Netherlands   32            4627

  Dr.         Andrew Lever         Editor                Cambridge University           Cambridge       UK                16            1591

  Dr.         Mark Wainberg        Editor                McGill University              Montreal        Canada            34            8457

  Dr.         Masahiro Fujii       Editor                Niigata University             Niigata         Japan             18            1410

  Dr.         Michael Lairmore     Editor                Ohio State University          Columbus        USA               17            1721

                                                                                                                                        

  Dr.         Michael Bukrinsky    Ed Board              George Washington Univ         Washington DC   USA               21            4247

  Dr.         Dong-yan Jin         Ed Board              Hong Kong U                    Hong Kong       China             20            1896

  Dr.         Klaus Strebel        Ed Board              NIH                            Bethesda        USA               21            3218

  Dr.         Tom J. Hope          Ed Board              U. Illinois                    Chicago         USA               23            3609

  Dr.         Serge Benichou       Ed Board              Cochin Institute               Paris           France            20            1466

  Dr.         Stephane Emiliani    Ed Board              Cochin Institute               Paris           France            15            1506

  Dr.         Olivier Bensaude     Ed Board              INSERM                         Paris           France            20            2046

  Dr.         Mauro Giacca         Ed Board              Int. Ctr. Genetics             Trieste         Italy             33            4577

  Dr.         Olivier Schwartz     Ed Board              Institut Pasteur               Paris           France            26            3865

  Dr.         Leonid Margolis      Ed Board              National Inst Child Health     Bethesda        USA               17            1394

  Dr.         Fatah Kashanchi      Ed Board              George Washington U.           Washington DC   USA               24            2071

  Dr.         Masao Matsuoka       Ed Board              Kyoto University               Kyoto           Japan             19            1554

  Dr.         Naoki Mori           Ed Board              University of the Ryukyus      Okinawa         Japan             24            1727

  Dr.         Chou-Zen Giam        Ed Board              Uniform Services Med Sch       Bethesda        USA               14            1288

  Dr.         David Derse          Ed Board              NCI                            Frederick       USA               12            1488

  Dr.         Tatsuo Shioda        Ed Board              Osaka Univ                     Osaka           Japan             21            1605

  Dr.         John Semmes          Ed Board              Eastern Virginia Med College   Norfolk         USA               23            2230

  Dr.         John Hiscott         Ed Board              McGill Univ.                   Montreal        Canada            37            6134

  Dr.         Fabrizio Mammano     Ed Board              INSERM                         Paris           France            14            1485

  Dr.         James K. Hildreth    Ed Board              Meharry Univ.                  Nashville       USA               23            2305

  Dr.         Finn Skou Pedersen   Ed Board              University of Aarhus           Aarhus          Denmark           17            1169

  Dr.         Janice Clements      Ed Board              Johns Hopkins Med School       Baltimore       USA               21            2879

  Dr.         Tahir A. Rizvi       Ed Board              United Arab Emirates Univ.     Al Ain          UAE               14            1133

  Dr.         Chris Aiken          Ed Board              Vanderbilt University          Nashville       USA               15            1593

  Dr.         Neil Almond          Ed Board              NIBSC                          Potters Bar     UK                12            1132

  Dr.         Stephen P. Goff      Ed Board              Columbia University            New York        USA               33            8325

  Dr.         Johnson Mak          Ed Board              Burnet Inst. Med. Research     Victoria        Australia         14            1094

  Dr.         Christine Kozak      Ed Board              NIH                            Bethesda        USA               27            6967

  Dr.         Greg Towers          Ed Board              Univ. College                  London          UK                14            1047

  Dr.         Graham Taylor        Ed Board              Imperial College               London          UK                20            1710

  Dr.         Eric Cohen           Ed Board              Univ. Montreal                 Montreal        Canada            31            5050

  Dr.         William Hall         Ed Board              University College Dublin      Dublin          Ireland           16            1293

  Dr.         Warner Greene        Ed Board              UCSF                           San Francisco   USA               35            8114

  Dr.         Jean-luc Darlix      Ed Board              U. Lyon                        Lyon            France            27            4816

  Dr.         Axel Rethwilm        Ed Board              U. Wuerzburg                   Wuerzburg       Germany           21            1784

  Dr.         Eric Freed           Ed Board              NCI                            Frederick       USA               27            3495

  Dr.         Toshiki Watanabe     Ed Board              Univ. of Tokyo                 Tokyo           Japan             18            1276

  Dr.         Mari Kannagi         Ed Board              Tokyo Med and Dental U         Tokyo           Japan             14            1189
  --------------------------------------------------------------------------------------------------------------------------------------------------------------

Gilt by association?
====================

How then should one choose where to publish one\'s manuscript? It has been raised that many scientists employ the \"gilt by association\" \[[@B9]\] approach, first sending their papers to high-visibility, high-IF journals, perhaps hoping that the \"free ride\" hypothesis works \[[@B4]\] and some of a journal\'s sheen would direct attention to and rub off on the work. However, there is no factual evidence that publishing a paper in a highly touted journal adds \"free citations\" to a paper other than those achieved by its content \[[@B4]\]. Indeed, this point seems to make intuitive sense. For example, a paper is the same paper if it were initially declined at *Cell*and then published in the *Journal of Virology*than if the paper were quickly accepted at *Cell*and did not have to make the rounds to the *Journal of Virology*. If the paper remains the same, should one sequence of events confer higher inherent quality to the same paper over another?

In the past, to support the interest of equal access to knowledge by scientists and students in developing economies who cannot afford subscription-based journals, I have argued that we have a responsibility to support Open Access publishing \[[@B10]\]. From a principled point of view, not to do so is poorly defensible. On the other hand, if one formulates decisions using a self-interest citation frequency driven perspective, evidence similarly supports that in head-to-head comparisons Open Access articles are cited more frequently than non-Open Access counterparts \[[@B11]\]. In today\'s publishing world, there are important roles to be played by both subscription and Open Access journals. However, as Open Access journals ascend in quality and visibility and globalization brings us closer to previously distant strangers, scientists confident in the inherent content and value of their papers might ask if they can tolerate the \"guilt associated with not supporting egalitarian access\"?

The above is a difficult question that each individual has to ponder. I am grateful for the answer that many authors and editorial board members of *Retrovirology*have provided to this question.
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